Amundi Buys 319,478 Shares of Biogen Inc. (NASDAQ:BIIB)

Amundi boosted its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 35.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,216,990 shares of the biotechnology company’s stock after buying an additional 319,478 shares during the period. Amundi owned approximately 0.84% of Biogen worth $183,461,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Larson Financial Group LLC grew its stake in shares of Biogen by 640.9% in the fourth quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 141 shares during the last quarter. Ashton Thomas Securities LLC purchased a new stake in Biogen during the 3rd quarter valued at about $33,000. SRS Capital Advisors Inc. bought a new stake in Biogen during the 4th quarter valued at about $33,000. Golden State Wealth Management LLC purchased a new position in Biogen in the fourth quarter worth about $41,000. Finally, Venturi Wealth Management LLC raised its holdings in Biogen by 73.8% in the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock worth $42,000 after buying an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Stock Performance

BIIB opened at $150.38 on Monday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. The stock has a market capitalization of $22.01 billion, a price-to-earnings ratio of 13.44, a PEG ratio of 1.51 and a beta of 0.01. The company has a fifty day moving average of $143.98 and a 200 day moving average of $166.18. Biogen Inc. has a fifty-two week low of $128.51 and a fifty-two week high of $238.00.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, sell-side analysts forecast that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on BIIB. Robert W. Baird raised their price target on shares of Biogen from $294.00 to $300.00 and gave the company an “outperform” rating in a research report on Friday, November 15th. StockNews.com lowered Biogen from a “strong-buy” rating to a “buy” rating in a report on Saturday, December 28th. Bank of America reaffirmed a “neutral” rating and set a $178.00 price target on shares of Biogen in a report on Tuesday, December 10th. Royal Bank of Canada reduced their price objective on Biogen from $231.00 to $225.00 and set an “outperform” rating for the company in a report on Thursday, February 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Biogen in a research note on Thursday, February 13th. Seventeen investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Biogen presently has a consensus rating of “Hold” and an average price target of $213.33.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.